Resilient Medical Corp
Promoting better healing by designing better devices.Co-founded by biomedical device designers and the inventors of our revolutionary Bravo™ device, Resilient combines decades of clinical experience and a history of expertise in translating emerging technologies.
One Bravo™ Device with Three Competitive Advantages
Bravo is specifically engineered for implantation during a standard lumpectomy, offering three major advantages. Firstly, its 3D mesh structure eliminates the necessity for follow-up cosmetic reconstruction, as it naturally integrates with the patient’s tissue over time. Secondly, Bravo serves as a radiocontrast marker for post-operative adjuvant therapies, which are common in most breast cancer lumpectomy cases. Thirdly, its polyester composition allows for degradation within approximately twelve months.
These combined benefits significantly reduce the invasiveness and trauma associated with the treatment, leading to a smoother and less distressing recovery for breast cancer patients.
Patented Design Promotes Better Procedures and Better Healing with Less Pain
The current standard for treating lumpectomy patients involves closing the surgical site and allowing the resulting void to heal naturally, without additional support. While lumpectomies present fewer complications than mastectomies, including lower patient risk, cost, and shorter surgical times, they often neglect patient healing and cosmetic restoration. Patients face risks such as painful and debilitating breast tissue collapse, as there are no implantable support devices available.
Recent studies highlight the need for improved cosmetic solutions, as current options like lipofilling and adipose grafts require additional cancer screening and have up to a 40% graft failure rate. Consequently, patient satisfaction with lumpectomies can be comparable to mastectomies in the short term. However, during the healing process, satisfaction may decline due to breast asymmetry. Research indicates that more extensive breast tissue removal is linked to decreased patient satisfaction.
Uniquely Positioned to Support a Large Market Gap
Resilient’s Bravo device is the only device capable of addressing cosmetic limitations from lumpectomies in an estimated 20% of the lumpectomy device market. Based upon patient testimonials and clinician feedback, an estimated 10% of the lumpectomy device market is open to conversion. Another 25% of the lumpectomy market is interested, but unaware, of alternative devices. Finally, approximately 15% of mastectomy patients base their surgical decision on cosmetic reasons and risk avoidance associated with current treatments.
Annual Number of New Diagnoses in the US
%
Percentage of Breast Cancer Patients Who Opt for Surgery
Our Team of Experts
Andrew Weems, Ph.D., Founder and CEO
Resilient Medical Corp
Dr. Andrew Weems is the CEO and co-founder of Resilient Medical Corp, leading the aggressive commercialization of their innovative Bravo™ device. With over a decade of experience as an entrepreneur, biomedical engineer, researcher, and inventor, Dr. Weems has a proven track record in advancing medical technology.
Resilient Medical Corp’s flagship product, the Bravo™ device, is set to revolutionize breast cancer treatment by eliminating the need for follow-up cosmetic reconstruction and serving as a radiocontrast target for post-operative therapies. This results in a less invasive and traumatic experience for patients.
Dr. Weems is dedicated to pioneering biomedical engineering through cutting-edge research and innovative medical device solutions. Connect with him to explore collaborations, research opportunities, and the commercialization of groundbreaking medical technologies.
The Bravo™ is an investigational device and not for sale.